Speaker illustration

Doctor Thomas Hauser

Novartis Biomedical Research, Cambridge (United States of America)

A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of XXB750 in heart failure patients with reduced or mildly reduced ejection fraction

Event: ESC Congress 2024

Topic: Pharmacotherapy

Session: Smaller trials, trial updates, and other studies on heart failure (1)

Thumbnail